Jounce Therapeutics

$6.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.13 (-1.91%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell JNCE and other stocks, options, and ETFs commission-free!

About JNCE

Jounce Therapeutics, Inc. Common Stock, also called Jounce Therapeutics, is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. The listed name for JNCE is Jounce Therapeutics, Inc. Common Stock.

CEO
Richard Murray
Employees
130
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
266.61M
Price-Earnings Ratio
Dividend Yield
Average Volume
329.66K
High Today
$7.08
Low Today
$6.63
Open Price
$6.80
Volume
248.72K
52 Week High
$11.72
52 Week Low
$2.85

Collections

JNCE Earnings

-$0.82
$0.42
$1.66
$2.90
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 25, Pre-Market

You May Also Like